The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Phoxilium® reduces hypophosphataemia and magnesium supplementation during continuous renal replacement therapy

På svenska

Author

Summary, in English

Background Although associated with severe clinical complications, phosphate remains a neglected ion. Additionally, phosphate balance during continuous renal replacement therapy (CRRT) is complex and multifunctional. The present retrospective study investigated the effects of phosphate-containing CRRT fluid on phosphate homeostasis. Methods We retrospectively analysed 112 patients treated with CRRT at Skane University Hospital, Sweden. The control group was treated with Hemosol® B0 (no phosphate; n = 36) as dialysis and replacement fluid, while the study group received Phoxilium® (phosphate; n = 76) as dialysis fluid and Hemosol® B0 as replacement fluid. Results Hypophosphataemia (

Publishing year

2016-04-01

Language

English

Pages

205-210

Publication/Series

Clinical Kidney Journal

Volume

9

Issue

2

Document type

Journal article

Publisher

Oxford University Press

Topic

  • Urology and Nephrology

Keywords

  • critically ill patients
  • CRRT
  • hypophosphataemia
  • intensive care medicine

Status

Published

ISBN/ISSN/Other

  • ISSN: 2048-8505